4d Molecular Therapeutics
Clinical trials sponsored by 4d Molecular Therapeutics, explained in plain language.
A biotech developing gene therapies using AAV vectors.
Trade on eToro (ad)Not investment advice. Company information is shown for context only. Clinical trials frequently fail.
-
Inhaled gene therapy aims to fix cystic fibrosis lungs
Disease control Recruiting nowThis phase 1/2 trial tests a single inhaled dose of gene therapy called 4D-710 in 30 adults with cystic fibrosis who cannot take standard modulator drugs. The therapy delivers a working copy of the CFTR gene directly to lung cells. The main goal is to check safety and side effect…
Phase: PHASE2 • Sponsor: 4D Molecular Therapeutics • Aim: Disease control
Last updated Jul 08, 2026 00:00 UTC
-
One shot to save sight? gene therapy trial aims to end frequent eye injections for wet AMD
Disease control Recruiting nowThis Phase 3 trial tests a single injection of 4D-150, a gene therapy, in 480 adults with wet age-related macular degeneration (AMD). The goal is to see if one treatment can maintain or improve vision and reduce the need for standard anti-VEGF injections like Eylea. Participants …
Phase: PHASE3 • Sponsor: 4D Molecular Therapeutics • Aim: Disease control
Last updated Jun 27, 2026 12:08 UTC
-
One-Time gene shot could cut eye injections for wet AMD
Disease control Recruiting nowThis study tests a gene therapy called 4D-150 for people with wet age-related macular degeneration (AMD), a leading cause of vision loss. The goal is to see if a single injection into the eye can safely reduce the need for regular anti-VEGF shots. About 215 adults aged 50 and old…
Phase: PHASE1, PHASE2 • Sponsor: 4D Molecular Therapeutics • Aim: Disease control
Last updated Jun 27, 2026 09:05 UTC